News Center
-91.jpg)
-
LaNova Medicines Moved to Its New Office at 999 Cailun Road in Zhangjiang Science Park
On August 2nd, 2021, LaNova Medicines moved to its brand-new office at 999 Cailun Road on Jinke Road in Zhangjiang Science Park, with expanded laboratory and office space. More than 40 employees gathered together in the hall of the new office, and the fou
2021-08-03Learn More
-
LM-102 Obtained China NMPA Clinical Trial Approval
LM-102 received China NMPA approval for its China phase I/II clinical study.
2021-06-23Learn More
-
LM-102 Obtained FDA Clinical Trial Approval and Completed First Patient Dosing
LM-102 obtained FDA clinical trial approval early this year as a phase I clinical study designed to evaluate the safety and initial efficacy of LM-102.
2021-06-22Learn More
-
LM-302 Obtained FDA Clinical Trial Approval
Claudin 18.2 ADC LM-302 obtained US FDA clinical study approval. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-302.
2021-06-21Learn More
-
LM-302 Obtained FDA Orphan Drug Designation
Claudin 18.2 ADC LM-302 obtained FDA Orphan Drug Designation in May 2021 for indications of pancreatic, gastric, and gastroesophageal junction cancers.
2021-05-12Learn More
-
LaNova Medicines Successfully Completed Series A Financing
In November 2020, LaNova Medicines completed the series A financing with Qiming Venture Partners as the leading investor and China Renaissance as the financial adviser. Investors also include global or domestic well-known PE / VCs, such as TF Capital, Yin
2020-12-12Learn More